NVO

$NVO

Novo Nordisk A/S

Danish pharma giant behind Ozempic and Wegovy weight-loss treatments.

Healthcare
$40.48
-1.11 (-2.68%)
Day Range$40.23 - $40.93
Prev Close$41.60

NVO key facts as of November 14, 2026

Latest AI research report
NVO Stock: Pipeline, Valuation and Key Risks (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Hold (0 Strong Buy, 3 Buy, 10 Hold, 1 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$42.33 mean (range $40.00 to $47.00) (as of November 17, 2026)
Sector
Healthcare
Analyst Rating
Hold
3 Buy / 10 Hold / 1 Sell
Price Target
$42.33
4.6% upside
Subscribers
2
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

NEUTRAL

NVO Stock: Pipeline, Valuation and Key Risks

Novo Nordisk reported a quarterly EPS beat and submitted etavopivat for regulatory review, adding to its pipeline beyond diabetes and obesity medicines. Yet analyst targets sit close to the Friday close, the shares remain well below their 52-week high, and available financial feeds contain conflicting per-share figures.

Nov 14, 2026

NVO FAQ

What is StockAlpha's latest view on NVO?

StockAlpha's latest AI research report on Novo Nordisk A/S (NVO), "NVO Stock: Pipeline, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Novo Nordisk reported a quarterly EPS beat and submitted etavopivat for regulatory review, adding to its pipeline beyond diabetes and obesity medicines. Yet analyst targets sit close to the Friday close, the shares remain well below their 52-week high, and available financial feeds contain conflicting per-share figures.

When was the NVO research last updated?

The most recent NVO report was published on November 14, 2026.

What do analysts expect for NVO?

As of November 1, 2026, the analyst consensus on NVO is Hold (0 Strong Buy, 3 Buy, 10 Hold, 1 Sell, 0 Strong Sell). As of November 17, 2026, the analyst price target is $42.33 mean (range $40.00 to $47.00).

Is this NVO research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring